Evidence map›Paper›PMID 26889809›Full record

ReviewNeuron2016

DREADDs for Neuroscientists.

Bryan L Roth

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Neuron, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06027190 (To Investigate the Clinical Efficacy of Optical 3D Navigation Repetitive Transcranial Magnetic Stimulation), which is not on this map. Cited by 995 papers.

0numbers the graph read from it
0cells of the map it votes in
995citing papers in PubMed
76.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06027190 nanot yet recruitingnot on this mapstarted 2024, after this paper: background citation

To Investigate the Clinical Efficacy of Optical 3D Navigation Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Achalasia, Optimize the Treatment Parameters, and Provide a Noninvasive Treatment Strategy for Achalasia

TypeinterventionalSponsorZhang NinaRan2024 to 2026Enrolled112ConditionsEsophageal Achalasia, Transcranial Magnetic Stimulation, Repetitive, Vagus Nerve Motor Disorder, Functional Magnetic Resonance ImagingArmsRepetitive transcranial magnetic stimulation, Sham
3 · Its place in the literature

Who cites it

995 citing papers in PubMed, 1,751 citations in OpenAlex.

  1. Article
  2. Overview of the DREADDs chemogenetics and the patent landscape of their actuators.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  3. A Critical Time Window of Neocortex Modulation for Remote Fear Memory in Rats and Humans.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Engineering Neuronal Network Connectivity Through Precise and Scalable Electrical Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  19. Article
  20. Article

935 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Bryan L RothDepartment of Pharmacology, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC 27514, USA. Electronic address: bryan_roth@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

Screening CoreU19MH082441 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CARON, MARC G., WETSEL, WILLIAM C · 2007 to 2016
$15.2M
Structure-Function of Opioid ReceptorsP01DA035764 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEREZOV, VADIM, ROTH, BRYAN L. · 2014 to 2018
$7.1M
Diterpines as Selective Kappa Opioid Receptor AgonistsR01DA017204 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L. · 2003 to 2014
$3.2M
DREADD2.0: AN ENHANCED CHEMOGENETIC TOOLKITU01MH105892 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JIN, JIAN, KASH, THOMAS L. · 2014 to 2016
$3.0M
NIDA NIH HHS P01 DA035764NIDA NIH HHS R01 DA017204NIMH NIH HHS U01 MH105892NIMH NIH HHS U19 MH082441NIMH NIH HHS UO1MH105892
6 · The paper itself

Abstract

To understand brain function, it is essential that we discover how cellular signaling specifies normal and pathological brain function. In this regard, chemogenetic technologies represent valuable platforms for manipulating neuronal and non-neuronal signal transduction in a cell-type-specific fashion in freely moving animals. Designer Receptors Exclusively Activated by Designer Drugs (DREADD)-based chemogenetic tools are now commonly used by neuroscientists to identify the circuitry and cellular signals that specify behavior, perceptions, emotions, innate drives, and motor functions in species ranging from flies to nonhuman primates. Here I provide a primer on DREADDs highlighting key technical and conceptual considerations and identify challenges for chemogenetics going forward.

Indexed as

Drug DesignTranslational Research, BiomedicalAnimalsHumansLigandsMolecular Targeted TherapyReceptors, NeurotransmitterSignal TransductionLigandsReceptors, Neurotransmitterchemical biologychemogeneticDREADDsynthetic biology

Identifiers

PMID26889809
PMCPMC4759656
OpenAlexW2275148408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.